Bacil Pharma Limited concluded its 39th Annual General Meeting on September 23, 2026, approving key governance changes including the elevation of Chaitali Kalpataru Shah to Managing Director and the appointment of new statutory auditors. The meeting, conducted via video conferencing, saw attendance from 66 members.

Governance and leadership updates

The shareholders passed a special resolution to change the designation of Chaitali Kalpataru Shah (DIN: 11167778) from Executive Director to Managing Director. Additionally, the company reappointed three independent directors for another term:

• Omprakash Pyarelal Sonar (DIN: 11031877)
• Vivek Mukesh Yadav (DIN: 11033957)
• Mahesh Singh (DIN: 11814569)

Anil Singh (DIN: 09338444) was also reappointed as a Non-Executive Non-Independent Director. These appointments signal a continuation of the current board's strategic direction.

Financial oversight and capital structure

The meeting addressed financial reporting and capital adjustments. Shareholders approved the adoption of the audited financial statements for the fiscal year ended March 31, 2026. A significant operational change involved the appointment of M/s Sarang Shivajirao Chavan & Associates Chartered Accountants (FRN: 159649W) as the new Statutory Auditors, replacing the previous firm.

Furthermore, an ordinary resolution was passed to increase the authorized share capital of the company, necessitating an alteration to the capital clause in its memorandum of association. This move typically provides flexibility for future fundraising or corporate actions.

Voting results and compliance details

The AGM was held in compliance with Ministry of Corporate Affairs and SEBI circulars allowing virtual meetings. Voting was facilitated through remote e-voting by NSDL, with a scrutinizer appointed to ensure transparency. The scrutinizer report, submitted on September 24, 2026, confirmed that all resolutions were passed with requisite majority.

The detailed voting outcomes for key resolutions are as follows:

The scrutinizer, CS Ramesh Chandra Bagdi of Ramesh Chandra Bagdi & Associates, verified the results using data from NSDL. The e-voting reports containing lists of members who voted for and against each resolution have been sealed and handed over to the Company Secretary for safekeeping.

Bacil Pharma has scheduled its 39th annual general meeting for September 23, 2026, to approve a significant increase in authorized share capital and key leadership changes. The board also confirmed no dividend for FY26.

The meeting will be conducted via video conferencing or other audio-visual means (VC/OAVM) in compliance with Ministry of Corporate Affairs and SEBI circulars. The register of members and share transfer books will remain closed from September 17 to September 23, 2026. Members holding shares as on the cut-off date of September 18, 2026, are eligible to vote through remote e-voting facilitated by NSDL.

Board Meeting Outcomes

The board approved several key resolutions during its meeting on August 29, 2026. The primary focus was on corporate governance matters and structural adjustments to the company’s capital base.

Leadership Changes

A notable development is the proposed change in designation of Chaitali Kalpataru Shah. The board seeks shareholder approval to elevate her role from Executive Director to Managing Director, effective August 25, 2026. This change requires a special resolution at the upcoming AGM. She will hold office until July 28, 2029.

Additionally, the board appointed two new directors on August 25, 2026: Anil Singh as Non-Executive Director and Mahesh Singh as Non-Executive Independent Director. Their appointments are subject to regularization by shareholders at the AGM. The board also seeks re-appointment of Omprakash Pyarelal Sonar and Vivek Mukesh Yadav as Non-Executive Independent Directors. Ms. Shah retires by rotation at this AGM and offers herself for re-appointment as a director.

Financial Performance: Other Income Drives PBT

For FY26, Bacil Pharma reported zero revenue from operations, consistent with FY25. However, total revenue rose to ₹123.52 lakh from ₹66.14 lakh in the prior year, driven entirely by other income. Profit before tax more than doubled to ₹99.02 lakh from ₹40.76 lakh. Despite this operational profitability, the company reported a net loss after tax of ₹61.88 lakh, compared to a profit of ₹40.05 lakh in FY25.

The reversal from profit to loss was primarily due to other comprehensive income (OCI) losses of ₹217.43 lakh, arising from fair value adjustments on investments. In contrast, OCI loss in FY25 was minimal at ₹0.36 lakh.

What the Numbers Show

The divergence between profit before tax and net loss highlights the company’s current reliance on non-operational activities. With zero revenue from core pharmaceutical operations, the business model remains investment-driven. The significant OCI loss indicates volatility in the fair value of its financial assets, which currently stand at ₹2,424 lakh on the balance sheet. While cost control measures kept expenses down to ₹24.50 lakh, the lack of operational cash flow generation remains a key structural characteristic of the company’s current financial profile.

Capital Structure Adjustment

The company proposes to increase its authorized share capital from ₹20 crore (2 crore equity shares) to ₹70 crore (7 crore equity shares). Each share has a face value of ₹10. The new shares will rank pari passu with existing equity shares. This move aims to broaden the capital structure and meet future funding requirements.

Auditor Appointment

The board recommends the appointment of M/s Sarang Shivajirao Chavan & Associates Chartered Accountants as statutory auditors. If approved, they will hold office from the conclusion of the 39th AGM until the conclusion of the 43rd AGM. This replaces the previous auditors, Laxmikant Kabra & Co LLP, who resigned in August 2025.